about
Main roads to melanomaGain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndromeRASAL3, a novel hematopoietic RasGAP protein, regulates the number and functions of NKT cellsAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsLessons learned from next-generation sequencing in head and neck cancerRAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expressionCombined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and ErkRAS oncogenes: weaving a tumorigenic webSolving the puzzle of metastasis: the evolution of cell migration in neoplasms.Label-free cancer cell detection with impedimetric transducersMetastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation.Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modulesMechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.RAS Interaction with PI3K: More Than Just Another Effector PathwayDirect Ras Inhibitors Identified from a Structurally Rigidified Bicyclic Peptide Library.Induction of nonapoptotic cell death by activated Ras requires inverse regulation of Rac1 and Arf6Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.The antagonism between MCT-1 and p53 affects the tumorigenic outcomes.Targeted therapy for melanoma: a primer.Inhibition of Ras-Effector Interaction by Cyclic Peptides.Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colonImmunohistochemistry - microarray analysis of patients with peritoneal metastases of appendiceal or colorectal originDifferential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformationConcurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer.Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer.Cellular changes in boric acid-treated DU-145 prostate cancer cells.The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status.The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression.Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity.Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways.Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutantsPrevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.New treatment in advanced thyroid cancer.Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics.Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling.RAS and downstream RAF-MEK and PI3K-AKT signaling in neuronal development, function and dysfunction
P2860
Q21245465-3F167049-0FDF-499F-8174-FB39DB3B682BQ24296397-C3EC852A-E9F4-4C17-BB04-1992711687F1Q24317577-07DEAAFB-EB45-4A0E-B506-287EEDA0DD2CQ26751344-1836EC3C-8255-4427-8E75-D1F12EECD699Q26782222-A440E5AC-4DC7-4AE8-BD87-E4C2DDDE3CABQ26795735-70CDA14E-F636-4E27-91BA-278403F8AFB3Q27009209-2CA1A243-57D5-4AE5-AB8A-6A96F616D263Q27320277-DA9EF3F0-17B0-4176-B494-64A4CFF7C860Q27852093-BAF92123-D108-49D0-BF32-C89F5D1DF8ECQ28243414-23000188-EAD1-4781-9AF0-8C08401E6FC3Q28250360-43A303E1-8880-40D4-9B29-32064B0FC897Q33351178-29556BDC-0BDD-40EA-A651-5A3E7CDDB5F3Q33553054-35E5BD8E-B63F-44F1-8F1D-BBE087275197Q33647719-A829AFC7-C743-4C32-989C-2452C282ACC5Q33738285-F7157078-C1C8-4C00-B070-71E7DCAA69F8Q33755906-F269ED03-984A-43BA-911E-4853A83D75D2Q34005661-7F9B750F-F41D-4C7F-B3A0-CD550EB8E49BQ34202692-46960D6D-7E80-496C-BB88-CBD7137ABD2FQ34271187-FCBB8382-ED81-44D6-AD9A-4A2D4BC3C4B1Q34365365-E0A58C10-AC28-475E-AA15-425CC7FE052FQ34365949-BC7BB0DF-5669-41C6-A769-910ADAD5EF89Q34481803-3CB1277E-A790-4679-96BD-380B40822044Q34540273-9AC6A44A-DC4B-43B5-A669-D6F1ECF21D98Q34668051-439E96FA-AF3F-4B38-9B00-4B5DCE78053DQ34749595-64986880-B9C3-4977-A478-DB8FF4B752D0Q34867868-938F0849-3FB3-4840-A0A6-64C2E1169739Q34989115-E8FA25A8-789E-4D82-A28B-DD422550ED92Q35161368-CF2C1689-3046-401C-9C25-880F1D9625C5Q35213124-EEAE55D8-0359-43FC-B3E5-A94DD7A516BAQ35551024-A798C2D2-03C3-45F0-98FA-0091649F5319Q35555401-A7C8B353-BBD7-40E2-8C36-CA0A370EA0F5Q35688212-8C21BDA0-8294-49FB-8406-D3DC2FBEAFFCQ35748395-81DDC2CF-801E-4F5C-941D-84F907CEBE4EQ36180749-412556C4-C0FF-43C4-8BF2-FCDAFFE01583Q36277286-4E67F7C1-C182-468F-9145-C53F73A7E7B0Q36346491-2678AA40-D28C-4D6C-BA7D-9725DA69C1CAQ36361115-A0FF3419-5947-4F70-8112-D7F220FD86DDQ36537788-71F4B8CE-FA88-42F9-BF37-7100A3A9BA0FQ36545077-E0728943-35EC-426D-B038-718B68E50ECCQ36580617-7F16581C-927A-41F4-B9DF-4F2440BBDCDB
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Oncogenic Ras in tumour progression and metastasis.
@ast
Oncogenic Ras in tumour progression and metastasis.
@en
type
label
Oncogenic Ras in tumour progression and metastasis.
@ast
Oncogenic Ras in tumour progression and metastasis.
@en
prefLabel
Oncogenic Ras in tumour progression and metastasis.
@ast
Oncogenic Ras in tumour progression and metastasis.
@en
P2860
P356
P1433
P1476
Oncogenic Ras in tumour progression and metastasis.
@en
P2093
Klaudia Giehl
P2860
P304
P356
10.1515/BC.2005.025
P577
2005-03-01T00:00:00Z